Latest Breaking News On - Rial 2257 kyg2050p1028 - Page 1 : comparemela.com

HONG KONG, Feb. 9, 2022 /PRNewswire/ Sirnaomics Ltd. , a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the start of a Phase I clinical trial for. | February 9, 2022

United statesMichael molyneauxPatrick luLysine coSirnaomics ltdPrnewswire sirnaomics ltdCompany or sirnaomicsExecutive directorChief medical officerHistidine lysine co polymerSirnaomics ltd stock exchangePress releaseRial 2257 kyg2050p1028